Mystery behind odd-shaped blood cancer cells revealed
Researchers have found that the Lamin B1 mutation causes odd-shaped nuclei in blood cancer cells, which may lead to improved care for leukaemia patients.
List view / Grid view
Researchers have found that the Lamin B1 mutation causes odd-shaped nuclei in blood cancer cells, which may lead to improved care for leukaemia patients.
Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
CRISPR-Cas9 and stem cell technologies have been used to create a cellular model of acute myeloid leukaemia, revealing therapeutic targets.
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
Researchers have found they can make leukaemia cells vulnerable by dislodging leukaemia stem cells from a tumour-promoting niche.
Researchers have discovered that disrupting the Gdpd3 gene significantly reduced chronic myelogenous leukaemia relapse in mice.
The study evaluating Down syndrome endothelial cells presented novel drug targets for leukaemia and suggested why DS patients may be at greater risk from the cancer.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
By deleting the CISH gene from natural killer cells made from iPSCs, researchers say they have effectively treated leukaemia in vivo and in vitro.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.